Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody specifically designed to target sialic acid-binding Ig-like lectin 8 (SIGLEC8). This antibody promotes apoptosis in interleukin-5 (IL-5)-activated eosinophils and effectively inhibits immunoglobulin E (IgE)-mediated mast cell activation. Lirentelimab is primarily utilized in research focused on eosinophilic gastritis and duodenitis, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these conditions.
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody specifically designed to target sialic acid-binding Ig-like lectin 8 (SIGLEC8). This antibody promotes apoptosis in interleukin-5 (IL-5)-activated eosinophils and effectively inhibits immunoglobulin E (IgE)-mediated mast cell activation. Lirentelimab is primarily utilized in research focused on eosinophilic gastritis and duodenitis, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these conditions.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
